Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.43 |
| ▸ | JAK2 | O60674 | 16/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22989504 | 0.86 | JAK1 (0.41) | JAK1JAK2MEN1ALDH1A1MAPT | |
| SCHEMBL24359182 | 0.81 | NR1H2 (0.43) | JAK1JAK2GPR119 | |
| SCHEMBL24359183 | 0.80 | USP2 (0.40) | JAK1JAK2ALDH1A1GPR119 | |
| SCHEMBL27221499 | 0.80 | USP2 (0.40) | JAK1JAK2GPR119 | |
| SCHEMBL9921830 | 0.80 | MEN1 (0.44) | JAK1JAK2MEN1ALDH1A1MAPT | |
| SCHEMBL26148291 | 0.79 | MEN1 (0.43) | JAK1JAK2MEN1ALDH1A1MAPT | |
| SCHEMBL22989493 | 0.78 | JAK1 (0.45) | JAK1JAK2MEN1ALDH1A1MAPT | |
| SCHEMBL2324364 | 0.78 | OPRM1 (0.31) | JAK1JAK2 | |
| SCHEMBL346187 | 0.78 | DDB1 (0.40) | JAK1JAK2GPR119 | |
| SCHEMBL25270241 | 0.78 | MEN1 (0.45) | JAK1JAK2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | JAK1 1884/4885JAK2 2008/4885MEN1 812/4885 |
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | JAK1 962/4885JAK2 230/4885MEN1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.